Company intelligence / Profile preview

Shanghai AngioCare Medical Technology

Shanghai, Shanghai Shi / Shanghai City, Chinaeurointervention.pcronline.com ↗

Ownership: Private
Development stage: Other

Overview

Shanghai AngioCare Medical Technology has developed the Iberis Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System, which received approval from China's National Medical Products Administration in February 2025 for treating hypertension. The company also develops bioresorbable scaffold systems for coronary and peripheral artery diseases, with multiple ongoing or completed clinical trials demonstrating safety and efficacy.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Terumo Corporation

Beyond the preview

Go deeper on Shanghai AngioCare Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai AngioCare Medical Technology.

Explore the full profile